Propanc Biopharma, Inc.
For the period ended Mar 31, 2026. Filed May 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 14, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Defaults Upon Senior Securities
Item 3. Defaults Upon Senior Securities.
As of March 31, 2026, we were in default under certain loans to related parties amounting $211,545 and accrued interest of $50,213, as of March 31, 2026, subsequent to their maturity date. We are currently in discussions with such lender to extend such maturity date. See “Note 5 and 6” to our unaudited condensed consolidated financial statements in Part I of this Quarterly Report for additional information.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.